Clinical Trials Browser

Phase 2 × Lymphoma, Non-Hodgkin × ublituximab × Clear all

NCT03207256 2022-07-21

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell